NTLA — Intellia Therapeutics Inc

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

About Intellia Therapeutics Inc

Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats ("CRISPR")/CRISPR associated 9 ("Cas9") technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$14.09
Market Cap$1.63B
Float112.9M
Shares Outstanding118.9M
Price/Sales (TTM)24.09
vs. Analyst Target+90.2% to analyst PT
Operating Margin (TTM)-428.86%
Revenue (TTM)$67.7M
Dividend RateNone
Analyst Target Price$26.80 (29 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 $58.0M -$126M $58.0M -$130M
2021 $33.1M -$260M $33.1M -$261M
2022 $52.1M -$474M $44.5M -$451M
2023 $36.3M -$481M $27.3M -$506M
2024 $57.9M -$519M $47.6M -$524M
2025 $67.7M -$413M $51.7M -$397M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Mar 2025 $16.6M -$114M
Jun 2025 $14.2M -$101M
Sep 2025 $13.8M -$101M
Dec 2025 $23.0M -$95.8M

Ownership & Float

Insider Ownership4.0%
Institutional Ownership77.4%
Short Float34.4%
% of All Funds Holding3.32%
Number of Funds Holding256

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$13.40Near-term / short-term trend
Weekly40-Week SMA$13.09Medium-term trend
Weekly80-Week SMA$11.86Cyclical trend (business cycle)
Weekly200-Week SMA$26.19Secular trend (multi-year)
Monthly10-Month SMA$12.65Near-term monthly trend
Monthly20-Month SMA$11.62Medium-term monthly trend
Monthly40-Month SMA$21.00Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$9.30 support 1.15x 3 months ago
$17.30 resistance 2.21x 6 months ago
$7.00 support 1.49x 10 months ago
$20.50 resistance 1.77x 18 months ago
$27.40 resistance 1.00x 24 months ago

Historical Earnings Reactions (41 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap -0.23% 0.07% 51.22% 10.45% -25.77%
1 Day -0.88% -0.37% 43.90% 14.33% -22.73%
1 Week -0.77% 0.40% 50.00% 24.44% -31.81%
2 Weeks 0.09% -2.68% 42.50% 48.52% -36.33%
1 Month 0.64% -1.36% 42.50% 73.94% -34.53%

Next earnings: May 14, 2026 (3 days away)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

MonthAvg ReturnWin RateSamples
Jan4.7%50.0%10
Feb6.5%70.0%10
Mar-6.9%20.0%10
Apr-2.9%50.0%10
May0.2%22.2%9
Jun23.0%90.0%10
Jul4.4%60.0%10
Aug2.1%50.0%10
Sep-1.1%20.0%10
Oct-10.6%20.0%10
Nov7.8%60.0%10
Dec-8.4%30.0%10

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday 0.47% 52.0% 469
Tuesday 0.09% 49.7% 517
Wednesday 0.16% 49.8% 514
Thursday -0.13% 47.9% 505
Friday -0.04% 48.2% 506

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 77.4%

Insider Transactions — Smart Summary

Total insider ownership: 4.0%

12-Month Insider Activity Summary

Total Filings18
Net Value-$1.4M
Net Shares Change172,165
% of Float0.2%
C-Suite Filings15
Clusters Detected2

Key Insiders

NameTitleNet ValueFilingsActivity
Cohen Fred E +$1.4M 1 1 buy
CHASE WILLIAM J +$1.0M 1 1 buy
BASTA JAMES EVP, General Counsel -$112,443.95 2 2 sell
Lebwohl David EVP, Chief Medical Officer -$109,626.63 1 1 sell
Clark Eliana EVP, Chief Technical Officer -$95,997.61 2 2 sell
Schultes Birgit C EVP, Chief Scientific Officer -$78,358.68 1 1 sell
Dulac Edward J III EVP, Chief Financial Officer -$58,750.59 1 1 sell
Dube Michael P VP, Chief Accounting Officer -$27,528.69 1 1 sell

Transaction Clusters

PeriodFilingsInsidersNet ValueSeniority
2025-07-02 – 2025-07-03 3 3 -$64,009.02 2 C-suite
2026-01-07 – 2026-01-07 8 8 +$630,361.23 7 C-suite

Significant Filings

DateInsiderTitleNet ValuePrice After
2026-03-03 BASTA JAMES EVP, General Counsel -$16,687.58 Transaction at $13.78, now +2.2%
2026-03-03 Clark Eliana EVP, Chief Technical Officer -$8,364.46 Transaction at $13.78, now +2.2%
2026-01-07 Cohen Fred E +$1.4M Transaction at $9.35, now +50.7%
2025-08-22 CHASE WILLIAM J +$1.0M Transaction at $10.03, now +40.5%
2026-01-07 Schultes Birgit C EVP, Chief Scientific Officer -$78,358.68 Transaction at $9.21, now +53.0%
2026-01-07 Lebwohl David EVP, Chief Medical Officer -$109,626.63 Transaction at $9.21, now +53.0%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Intellia Therapeutics Inc (NTLA) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for NTLA on Trend Edge →